Q2 non-GAAP EPS of $1.92 exceeds expectations by $0.16, while revenue of $199.9M misses by $1.05M.
Collegium Pharmaceutical reported Q2 non-GAAP earnings per share of $1.92, beating estimates by $0.16. Revenue reached $199.9 million, a 6.3% year-over-year increase but $1.05 million below forecasts.
Adjusted EBITDA rose 8% to $113.8 million from $105.1 million in the prior-year quarter. The company generated $71.3 million in cash from operations and ended the quarter with $129.5 million in cash and equivalents.